Matthew L. Kaplan serves as Executive at Nuvectis Pharma, Inc., where they oversee executive responsibilities. Since joining the company, Matthew L. Kaplan has executed 5 insider transactions totaling $114.9K, demonstrating a bullish approach to their equity position. Their most recent transaction on Nov 5, 2025 involved purchasing 11,000 shares valued at $64.2K.
Matthew L. Kaplan currently holds 124,760 shares of Nuvectis Pharma, Inc. (NVCT), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Matthew L. Kaplan has been a net buyer of NVCT stock. They have purchased $114.9K and sold $0 worth of shares.
Matthew L. Kaplan's most recent insider trade was on Nov 5, 2025, when they purchased 11,000 shares at $5.84 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Jun 16, 2023 | NVCT | $0 | Award | 18,000 | $N/A | Discretionary |
| May 12, 2022 | NVCT | $31.8K | Purchase | 1,823 | $17.47 | Discretionary |
| May 12, 2022 | NVCT | $18.8K | Purchase | 1,177 | $15.96 | Discretionary |